Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

FOR46 demonstrated encouraging preliminary clinical activity with a manageable safety profile. Targeting CD46 elicited an immune priming effect that was associated with clinical outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-03-26
DOI
https://doi.org/10.1200/jco-24-01989
Citations
9
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
13.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Elisabeth I. Heath, Eric Jay Small, Andrew Dorr, Jiaoti Huang et al.
9 citations
Journal of Clinical Oncology
Prostate Cancer Treatment and Research
13.67
article

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Elisabeth I. Heath, Eric Jay Small, Andrew Dorr, Jiaoti Huang, Alexander Cheung, Marc Nasoff, John Hunter, David A. Quigley, Matthew B. Rettig, Jill Abbey, Adam Foye, Lawrence H. Fong, David James VanderWeele, Arun K. Chumber, Rahul Aggarwal, Robert R. Flavell, Jacqueline Vuky, Stanley G. Leung, Bin Liu, Steven Wang
article en
9 citations

Abstract

FOR46 demonstrated encouraging preliminary clinical activity with a manageable safety profile. Targeting CD46 elicited an immune priming effect that was associated with clinical outcomes.

Journal of Clinical OncologyVol. 43(15)
Northwestern University (US), University of California, Los Angeles (US), Oregon Health & Science University (US), Duke University (US), University of California, San Francisco (US), Wayne State University (US), Fred Hutch Cancer Center (US), The Barbara Ann Karmanos Cancer Institute (US), Los Angeles Medical Center (US), Phusis Therapeutics (United States) (US), FibroGen (United States) (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Good health and well-being
Openalex Percentile: Top 1%
Prostate Cancer Treatment and Research
13.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.